We Are Crinetics


Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest


Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals announces August 2022 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

Crinetics VP of clinical endocrinology, Peter J. Trainer, M.D., will review preclinical and Phase 1 clinical results of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology